The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
SKYCLARYS Biogen Australia Pty Ltd
Product name
SKYCLARYS
Sponsor
Accepted date
Jul-2024
Active ingredients
omaveloxolone
Proposed indication
For the treatment of Friedreich’s ataxia.
Application type
A (new medicine)
Publication date
Jul-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.